Quality, comprehensiveness and excellence


Revisions Appendix III Manual 3.0 (Quantitative questionnaire)

April 15, 2021 Pharmacy with unit dedicated to Oncology (instead of Oncology Pharmacy) Definition accrual into prospective interventional trials:
Participants in cohort-based observational biomarker-driven studies are NOT included in the number forming the percentage for Designation. We do ask for the data of cohort-based observational studies (see question ), provided that they concern studies with a formal PI role from the centre, and approved by scientific and ethical review committees.


Revisions Appendix II Manual 3.0 (Qualitative questionnaire)

April 15, 2021 
When working on the template for the peer review report of Manual 3.0 as well as the IEEA accreditation of the OECI standards of Manual 3.0, we have noticed some revisions, which have not been taken over in the Manual 3.0, as this was published before the revisions were made. We herewith inform you of these minor changes:
  • Some standards have been upgraded to CORE standards: standard 12.5, 32.1, 40.1, 40.3, 40.9, 41.1, 41.3, 41.9, 46.2, 47.2, 50.6
  • One standard was downgraded from a CORE standard: standard 57.

Changes to the composition of the OECI A&D Board and Accreditation Committee

March 08, 2021 

We are happy to announce that Dr Jozsef Lovey, a present member of the Accreditation Committee and Medical Director of the National Institute of Oncology in Budapest, has agreed to chair the Committee, in succession to Prof Gunnar Saeter.  Gunnar has done an amazing job over the last 6 years, streamlining the committee’s work at a time of strong growth in the programme, and providing robust and detailed advice on accreditation decisions to the Accreditation & Designation Board.


OECI audits: from on-site to hybrid to 100% virtual

December 18, 2020 

The Covid-19 virus has a major impact on the way everyone works. This also applies to the work for the Accreditation and Designation programme of the OECI.

This spring, the audit for the Cancer Centre in Reggio Emilia was cancelled in a hurry after it became clear that the number of Covid-19 patients in the northern provinces of Italy was rapidly increasing at the end of February. The number of Covid-19 cases also increased rapidly in the rest of Europe.


Implementation Manual 3.0 OECI Accreditation & Designation Programme

December 18, 2020 

To help cancer centres implement a quality system for cancer care, OECI has developed standards and a peer review system. These standards are revised every 5 years. The revision process is a meticulous process, where we evaluate each standard, while also looking at new developments in cancer care.

The OECI Accreditation & Designation (A&D) Programme launched its second version of the revised standards and procedures, as described in Manual 3.0, in December 2019. The Manual can be downloaded from our website (oeci.eu/accreditation).


100 European Core Quality standards for cancer centres published

November 22, 2020 
In August 2020, the Accreditation and Designation Board of OECI published the results of two years revision work on the Quality Standards for our cancer centres in Europe. Part of this exercise was to select by consensus the Core Standards for quality care and research infrastructure which would be regarded as essential to apply across Europe, and which OECI will use as core requirements in every (re-)accreditation of a cancer centre, and require full evidence of compliance. .

100 European consensus Quality Standards for Cancer Centres

August 17, 2020 

The OECI A&D Board is proud to inform you that The Lancet Oncology has accepted our article '100 European consensus Quality Standards for Cancer Centres'. The article sets out the robust process by which OECI consulted many experts and arrived at a consensus of core quality standards (100 in number) which should become standard in European cancer centres to achieve high quality care, research and education.


Change in definition ‘Accrual into prospective interventional clinical trials’ Manual 3.0, effective immediately

July 23, 2020 

When working on the revision of the standards in 2019, the OECI A&D Board decided to consider changing the indicator for the Percentage of patients included in clinical trials. This was based on remarks made during the session during the Oncology Days in June 2019 in Bari, indicating that the definition did not take into account some developments related to biomarker-driven studies. However, after evaluating the first preliminary designations, the OECI A&D Board has concluded that the new definition for Manual 3.


Continuation of OECI A&D Peer reviews

July 16, 2020 

As our centres were dealing with the COVID-19 situation, OECI decided in March to postpone all planned site visits until Autumn 2020. In the past weeks the OECI A&D Board has investigated alternatives to start up the A&D Programme, which protect health professionals, patients and the OECI auditors and co-ordinators. .

In September 2020 the OECI A&D Programme will continue with hybrid virtual peer reviews.

1 2 3 4